William Pao
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.02%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 148
- Lung Cancer Diagnosis and Treatment 21
- Oncology 75
- Colorectal Cancer Treatments and Studies 27
- HER2/EGFR in Cancer Research 23
- Lung Cancer Research Studies 22
- Co-authors
- Vincent A. Miller (42 shared papers)Mark G. Kris (71 shared papers)Gregory J. Riely (48 shared papers)Maureen F. Zakowski (29 shared papers)Marc Ladanyi (51 shared papers)Katerina Politi (17 shared papers)Harold Varmus (9 shared papers)Juliann Chmielecki (15 shared papers)
- Journals
- Journal of Clinical Oncology (53 papers)Clinical Cancer Research (32 papers)Journal of Thoracic Oncology (16 papers)Cancer Research (8 papers)PLoS ONE (7 papers)
- Partner nations
- United StatesChinaGermany
In The Last Decade
William Pao
226 papers receiving 34.8k citations
William Pao's Hit Papers
Peers
Comparison fields: 5 of 155
- Pulmonary and Respiratory Medicine 21.4k
- Oncology 15.4k
- Cancer Research 6.0k
- Molecular Biology 12.0k
- Pathology and Forensic Medicine 1.9k
Countries citing papers authored by William Pao
This map shows the geographic impact of William Pao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Pao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Pao more than expected).
Fields of papers citing papers by William Pao
This network shows the impact of papers produced by William Pao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Pao. The network helps show where William Pao may publish in the future.
Co-authors
The 25 scholars most cited alongside William Pao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 229 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Hit paper breakdown → | 2004 | 3491 |
| 2 | Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain Hit paper breakdown → | 2005 | 2799 |
| 3 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers Hit paper breakdown → | 2013 | 1919 |
| 4 | KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Hit paper breakdown → | 2005 | 1229 |
| 5 | New driver mutations in non-small-cell lung cancer Hit paper breakdown → | 2011 | 881 |
| 6 | Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Hit paper breakdown → | 2010 | 867 |
| 7 | American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Hit paper breakdown → | 2009 | 754 |
| 8 | Acquired resistance to TKIs in solid tumours: learning from lung cancer Hit paper breakdown → | 2014 | 684 |
| 9 | Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Hit paper breakdown → | 2006 | 665 |
| 10 | Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Hit paper breakdown → | 2009 | 646 |
| 11 | Anchored multiplex PCR for targeted next-generation sequencing Hit paper breakdown → | 2014 | 640 |
| 12 | Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2004 | 630 |
| 13 | Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib Hit paper breakdown → | 2006 | 626 |
| 14 | HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation Hit paper breakdown → | 2012 | 561 |
| 15 | Syk tyrosine kinase required for mouse viability and B-cell development Hit paper breakdown → | 1995 | 538 |
| 16 | Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas Hit paper breakdown → | 2007 | 537 |
| 17 | Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions Hit paper breakdown → | 2005 | 515 |
| 18 | Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation Hit paper breakdown → | 2010 | 492 |
| 19 | Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay Hit paper breakdown → | 2011 | 477 |
| 20 | 2009 | 448 |
About William Pao
William Pao is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 229 papers that have together received 35.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (148 papers), Cancer Genomics and Diagnostics (44 papers), Colorectal Cancer Treatments and Studies (27 papers), HER2/EGFR in Cancer Research (23 papers), Lung Cancer Research Studies (22 papers), Lung Cancer Diagnosis and Treatment (21 papers), RNA modifications and cancer (14 papers) and Cancer therapeutics and mechanisms (13 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (21.4k citations), Oncology (15.4k citations), Cancer Research (6.0k citations), Molecular Biology (12.0k citations) and Pathology and Forensic Medicine (1.9k citations). William Pao has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Vincent A. Miller, Mark G. Kris, Gregory J. Riely, Maureen F. Zakowski, Marc Ladanyi, Katerina Politi, Harold Varmus, Juliann Chmielecki, Nicolas Girard and Robert T. Heelan. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Cancer Research and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.